Pfizer’s Covid-19 Vaccine is Safe for Children Ages 5-12 According to Company

Pfizer announced this morning that a Phase 2 Phase 3 trial showed it’s Covid-19 vaccine was safe and generated a ‘robust’ antibody response in children ages 5 to 11. The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. The trial used a 10 microgram dose which is smaller than the 30 microgram dose that was used in a trial for kids 12 and older. The results released today are the first for the age group and the data has not been peer-reviewed or published yet.

Participant’s immune responses were measured by looking at antibody levels in the blood and comparing those levels to a control group of 16 to 25 year olds who were given two-doses of the shot with the 30 microgram dose. According to Pfizer those levels compared with older people who received the larger dose demonstrated a ‘strong immune response in this cohort of children one month after the second dose.’ Pfizer is planning to submit the plans to the U.S. Food and Drug Administration for emergency use authorization soon.